JNJ | Weekly | Haru Insights

Johnson & Johnson (JNJ) is engaged in a high-stakes patent lawsuit with Bayer’s Monsanto unit over alleged infringement of US Patent No. 7,741,118, a foundational mRNA patent central to its COVID-19 vaccine—this legal battle poses a material threat to JNJ’s innovation narrative and could lead to substantial financial penalties or royalty obligations.
The permanent U.S. J-code reimbursement for Inlexzo, a key oncology asset, has been secured—this regulatory and payer validation is a major commercial milestone, directly boosting access, adoption, and revenue potential for the drug in Q3 and beyond.

JNJ’s Phase 3 Caplyta data for bipolar mania delivering nearly 50% response rates with rapid symptom relief validates its neuroscience pivot and strongly justifies the $14.6 billion Intra-Cellular Therapies deal, reinforcing leadership in high-need mental health markets.
The permanent J-code for Inlexzo is a strategic windfall—removing reimbursement uncertainty enables broad market access and accelerates revenue ramp, affirming payer confidence in JNJ’s oncology pipeline.
ICOTYDE’s long-term psoriasis data—including sustained clearance and efficacy in adolescents—positions it as a potential blockbuster oral IL-23 inhibitor, offering a superior adherence profile vs. injectables and disrupting a crowded treatment space.
Tremfya’s STAR study results showing MRI-confirmed structural improvement in axial psoriatic arthritis mark a clinical first for IL-23 inhibitors, cementing its leadership and justifying its $25B+ revenue franchise with irrefutable efficacy.
JNJ’s $16.89B free cash flow and 25.74% ROE reflect unmatched financial discipline, enabling consistent R&D, strategic M&A, and dividend strength—providing a powerful buffer against legal and commercial headwinds.

Johnson & Johnson (JNJ)[Tv]